Open access
Open access
Powered by Google Translator Translator

Randomized Trial: Aspirin for Primary Prevention of Cardiovascular Disease

31 Aug, 2018 | 03:06h | UTC

Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial – The Lancet (link to abstract – $ for full-text)

Commentaries: Aspirin Fails to Prevent CV Events in People at ‘Moderate’ Risk of Disease: ARRIVE – TCTMD (free) AND ARRIVE: New Findings Contribute to Growing Body of Evidence Surrounding Aspirin Use – American College of Cardiology (free) AND Daily Aspirin Fails to Lower CV Risk in Long-term, Primary Prevention ARRIVE Trial – Medscape (free registration required) AND Jury still out on aspirin a day to prevent heart attack and stroke – ESC Press Releases (free)

 


Stay Updated in Your Specialty

No spam, just news.